AR035352A1 - Anticuerpos anti-lt-beta-r humanizados - Google Patents

Anticuerpos anti-lt-beta-r humanizados

Info

Publication number
AR035352A1
AR035352A1 ARP010104807A ARP010104807A AR035352A1 AR 035352 A1 AR035352 A1 AR 035352A1 AR P010104807 A ARP010104807 A AR P010104807A AR P010104807 A ARP010104807 A AR P010104807A AR 035352 A1 AR035352 A1 AR 035352A1
Authority
AR
Argentina
Prior art keywords
beta
humanized antibodies
methods
humanized
antibodies
Prior art date
Application number
ARP010104807A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AR035352A1 publication Critical patent/AR035352A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos humanizados para LT-beta-R y métodos de uso de los mismos.
ARP010104807A 2000-10-13 2001-10-12 Anticuerpos anti-lt-beta-r humanizados AR035352A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
AR035352A1 true AR035352A1 (es) 2004-05-12

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104807A AR035352A1 (es) 2000-10-13 2001-10-12 Anticuerpos anti-lt-beta-r humanizados

Country Status (25)

Country Link
US (2) US7429644B2 (es)
EP (1) EP1326897A2 (es)
JP (1) JP2004532608A (es)
KR (1) KR20030041164A (es)
CN (1) CN1547590A (es)
AR (1) AR035352A1 (es)
AU (2) AU2002211747B2 (es)
BG (1) BG107802A (es)
BR (1) BR0114646A (es)
CA (1) CA2425809A1 (es)
CZ (1) CZ20031307A3 (es)
EA (1) EA006945B1 (es)
EE (1) EE200300179A (es)
GE (1) GEP20063752B (es)
HU (1) HUP0302573A2 (es)
IL (1) IL155340A0 (es)
IS (1) IS6779A (es)
MX (1) MXPA03003144A (es)
NO (1) NO20031642L (es)
NZ (1) NZ525793A (es)
PL (1) PL366307A1 (es)
SK (1) SK5672003A3 (es)
TR (2) TR200300478T2 (es)
WO (1) WO2002030986A2 (es)
YU (1) YU28503A (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
WO2004002431A2 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
AU2006311803C1 (en) 2005-11-04 2015-05-14 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
NZ572565A (en) * 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2666934A1 (en) * 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
TWI391401B (zh) 2006-11-02 2013-04-01 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
CN111253484A (zh) 2007-06-25 2020-06-09 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
PE20161440A1 (es) 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
MX2017005148A (es) 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
CN114671952A (zh) * 2015-07-14 2022-06-28 里姆蒙埃克斯特股份有限公司 具有改善的结合、功能和安全性特征的抗cd154抗体及其在人免疫治疗中的用途
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US20210188990A1 (en) 2019-12-11 2021-06-24 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
IL313258A (en) 2021-12-20 2024-08-01 Hoffmann La Roche Agonist LTBR antibodies and their component bispecific antibodies
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8228891A (en) 1990-06-27 1992-01-23 Biogen, Inc. Surface complexed lymphotoxin
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE397665T1 (de) 1992-12-04 2008-06-15 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
HUP9801746A3 (en) * 1995-01-26 2000-11-28 Biogen Idec Ma Inc Cambridge Lymphotoxin-alfa/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
NZ506529A (en) 1998-01-30 2002-12-20 Biogen Inc Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
WO2004002431A2 (en) 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
CN100473664C (zh) 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
WO2004058183A2 (en) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Also Published As

Publication number Publication date
US20090092601A1 (en) 2009-04-09
WO2002030986A2 (en) 2002-04-18
MXPA03003144A (es) 2004-12-06
CA2425809A1 (en) 2002-04-18
AU1174702A (en) 2002-04-22
EA006945B1 (ru) 2006-06-30
YU28503A (sh) 2006-05-25
IS6779A (is) 2003-04-11
KR20030041164A (ko) 2003-05-23
NO20031642D0 (no) 2003-04-10
EE200300179A (et) 2003-08-15
WO2002030986A3 (en) 2003-03-13
NZ525793A (en) 2008-04-30
EP1326897A2 (en) 2003-07-16
CN1547590A (zh) 2004-11-17
EA200300464A1 (ru) 2003-10-30
TR200300478T2 (tr) 2004-10-21
CZ20031307A3 (cs) 2003-10-15
TR200602095T2 (tr) 2007-02-21
SK5672003A3 (en) 2003-10-07
JP2004532608A (ja) 2004-10-28
IL155340A0 (en) 2003-11-23
HUP0302573A2 (hu) 2003-10-28
NO20031642L (no) 2003-06-13
BG107802A (bg) 2004-01-30
GEP20063752B (en) 2006-02-27
AU2002211747B2 (en) 2007-11-29
US20040058394A1 (en) 2004-03-25
PL366307A1 (en) 2005-01-24
US7429644B2 (en) 2008-09-30
BR0114646A (pt) 2006-02-21

Similar Documents

Publication Publication Date Title
AR035352A1 (es) Anticuerpos anti-lt-beta-r humanizados
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
CR10372A (es) Anticuerpos anti-tat226 e inmunoconjugados
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
AR027938A1 (es) Compuestos uracilo y utilizacion de los mismos
DE50105753D1 (de) Farbmittelmischung
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
ECSP088924A (es) Anticuerpos e inmunoconjugados y sus usos
CR8231A (es) Anticuerpos rg1 y uso de los mismos
DE60106954D1 (de) Resorcin-derivate
UY27192A1 (es) Inhibidores de peptido-deformilasa
NO20031860L (no) Kahalalid F
BR0015872A (pt) Agentes antitrombóticos
UY26556A1 (es) Compuestos calcilíticos
BR0110902A (pt) Inibidores de mmp-9/mmp-2
HN2000000056A (es) Nuevas formas cristalinas de un antibiotico macrolido
AR027954A1 (es) Encendedor de uso general
DK1311267T3 (da) Retroviral immunoterapi
DK1054691T3 (da) Antienzym-antistoffer til behandling af huden
BR0316544A (pt) Compostos calcilìticos
ATE256754T1 (de) Gerbstoff-/nachgerbstoffpräparationen
DE60232650D1 (de) Peptiddeformylaseinhibitoren
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento
DOP2002000329A (es) Composicion solida
UA3864S (uk) Комплект туристських меблів

Legal Events

Date Code Title Description
FA Abandonment or withdrawal